These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32935910)

  • 1. Onychomadesis following COVID-19 infection: Is there a relationship?
    Senturk N; Ozdemir H
    Dermatol Ther; 2020 Nov; 33(6):e14309. PubMed ID: 32935910
    [No Abstract]   [Full Text] [Related]  

  • 2. Isolated maculopapular eruption localized to head and neck: A cutaneous sign of COVID-19 infection.
    Farabi B; Atak MF
    Dermatol Ther; 2020 Nov; 33(6):e14468. PubMed ID: 33112023
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous lesions and COVID-19: Cystic painful lesion in a case with positive SARS-CoV-2.
    Goudarzi S; Dehghani Firouzabadi F; Dehghani Firouzabadi M; Rezaei N
    Dermatol Ther; 2020 Nov; 33(6):e14266. PubMed ID: 32882081
    [No Abstract]   [Full Text] [Related]  

  • 4. Cutaneous Hyperaesthesia in SARS-CoV-2 Infection: Rare but not Unique Clinical Manifestation.
    Krajewski PK; Maj J; Szepietowski JC
    Acta Derm Venereol; 2021 Jan; 101(1):adv00366. PubMed ID: 33320278
    [No Abstract]   [Full Text] [Related]  

  • 5. Urticaria in an infant with SARS-CoV-2 positivity.
    Proietti I; Mambrin A; Bernardini N; Tolino E; Balduzzi V; Maddalena P; Marchesiello A; Michelini S; Volpe S; Skroza N; Potenza C
    Dermatol Ther; 2020 Nov; 33(6):e14043. PubMed ID: 32697027
    [No Abstract]   [Full Text] [Related]  

  • 6. Maculopapular eruptions associated to COVID-19: A subanalysis of the COVID-Piel study.
    Català A; Galván-Casas C; Carretero-Hernández G; Rodríguez-Jiménez P; Fernández-Nieto D; Rodríguez-Villa A; Navarro-Fernández Í; Ruiz-Villaverde R; Falkenhain-López D; Llamas-Velasco M; Carnero-Gonzalez L; García-Gavin J; Baniandrés O; González-Cruz C; Morillas-Lahuerta V; Cubiró X; Figueras I; Selda-Enriquez G; Fustà-Novell X; Roncero-Riesco M; Burgos-Blasco P; Romaní J; Solà-Ortigosa J; García-Doval I
    Dermatol Ther; 2020 Nov; 33(6):e14170. PubMed ID: 32779280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous Endothelial Dysfunction and Complement Deposition in COVID-19.
    Tammaro A; Adebanjo GAR; Del Nonno F; Pezzuto A; Ramirez-Estrada S; Parisella FR; Rello J; Scarabello A
    Am J Dermatopathol; 2021 Mar; 43(3):237-238. PubMed ID: 33055532
    [No Abstract]   [Full Text] [Related]  

  • 8. Cutaneous manifestations of COVID-19: A case report and a new finding from Egypt.
    Farouk S; Sadek A
    Dermatol Ther; 2020 Nov; 33(6):e14038. PubMed ID: 32691948
    [No Abstract]   [Full Text] [Related]  

  • 9. Alopecia areata in a patient with SARS-Cov-2 infection.
    Sgubbi P; Savoia F; Calderoni O; Longo R; Stinchi C; Tabanelli M
    Dermatol Ther; 2020 Nov; 33(6):e14295. PubMed ID: 32909635
    [No Abstract]   [Full Text] [Related]  

  • 10. Enanthem in Patients With COVID-19 and Skin Rash.
    Jimenez-Cauhe J; Ortega-Quijano D; de Perosanz-Lobo D; Burgos-Blasco P; Vañó-Galván S; Fernandez-Guarino M; Fernandez-Nieto D
    JAMA Dermatol; 2020 Oct; 156(10):1134-1136. PubMed ID: 32667631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report: SARS-CoV-2-induced urticaria or just a concomitance?
    Fida M; Mala R; Pupo L; Dibra A; Nasto K
    Dermatol Ther; 2020 Nov; 33(6):e14250. PubMed ID: 32860461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies.
    Campos DMO; Fulco UL; de Oliveira CBS; Oliveira JIN
    J Evid Based Med; 2020 Nov; 13(4):255-260. PubMed ID: 33058394
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment.
    Martinez MA
    Front Immunol; 2021; 12():635371. PubMed ID: 33777024
    [No Abstract]   [Full Text] [Related]  

  • 14. An EUA for sotrovimab for treatment of COVID-19.
    Med Lett Drugs Ther; 2021 Jun; 63(1627):97-xx98. PubMed ID: 34181630
    [No Abstract]   [Full Text] [Related]  

  • 15. Cutaneous manifestations in hospitalized patients diagnosed as COVID-19.
    Askin O; Altunkalem RN; Altinisik DD; Uzuncakmak TK; Tursen U; Kutlubay Z
    Dermatol Ther; 2020 Nov; 33(6):e13896. PubMed ID: 32579756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colchicin treatment of COVID-19 presenting with cutaneous rash and myopericarditis.
    Recalcati S; Piconi S; Franzetti M; Barbagallo T; Prestinari F; Fantini F
    Dermatol Ther; 2020 Nov; 33(6):e13891. PubMed ID: 32584431
    [No Abstract]   [Full Text] [Related]  

  • 17. An EUA for bamlanivimab and etesevimab for COVID-19.
    Med Lett Drugs Ther; 2021 Apr; 63(1621):49-50. PubMed ID: 33830966
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
    Million M; Roussel Y; Gautret P; Raoult D
    Int J Antimicrob Agents; 2021 Jan; 57(1):106240. PubMed ID: 33408019
    [No Abstract]   [Full Text] [Related]  

  • 19. Coronavirus disease 2019 and epidermolysis bullosa: Report of three cases.
    Abdollahimajd F; Youssefian L; Pourani MR; Vahidnezhad H; Uitto J
    Dermatol Ther; 2020 Nov; 33(6):e14194. PubMed ID: 32794270
    [No Abstract]   [Full Text] [Related]  

  • 20. Urticaria in the times of COVID-19.
    Kaushik A; Parsad D; Kumaran MS
    Dermatol Ther; 2020 Nov; 33(6):e13817. PubMed ID: 32531079
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.